
Brand New In Box: A $215M Priority Review Voucher that Arrowhead Pharmaceuticals bought but no longer need prvwatch.com/news/brand-new-…

Tracking FDA Priority Review Voucher (PRV) issuances, sales, redemptions and other FDA/Biotech news.

Brand New In Box: A $215M Priority Review Voucher that Arrowhead Pharmaceuticals bought but no longer need prvwatch.com/news/brand-new-…



Spoke to an inventor-scientist today working on an ultra-rare pediatric disease treatment and they had never heard of the Priority Review Voucher program. I asked them to list every rare pediatric drug they knew and I then said they all earned PRVs, which currently sell for $200M


I think there is some context missing here. The Commissioner's National Priority Voucher Council has ten voting members that are responsible for voucher selection and approval decisions. Following the FDA leadership changes, six of the ten council positions appear to be vacant.
The US Food and Drug Administration has shelved the fast-track drug review initiative launched during the Trump administration by former Commissioner Marty Makary, according to six sources familiar with the matter and internal documents. reuters.com/world/us-fda-she…

This clip has lit up BioX and I dont agree with the hate. The AI labs have the capital, let them try, they either succeed and its great for humanity or they don't and we learn far more from the billions invested in some of these diseases that we currently barely understand.
Anthropic CEO predicts cancer, Alzheimer's, heart disease, mental illness will be cured in less than 10 years ACCELERATE

It’s rare for me to see a PRV acquisition and think why did they do that, this is one of those. I’ll be investigating probably too much than I should be over the next few days 🕵️♂️. Likely the next topic of my circular, I’ve had writers block for a while.
BioNTech $BNTX purchase Scholar Rock’s $SRRK Priority Review Voucher that they earned a couple of months ago for $205M




Cabaletta Bio $CABA plan to submit a BLA for their CAR-T in adult myositis in Q1 2028 but also intend to include data from their Ph1/2 trial in pediatric myositis to try and get a rare pediatric priority review voucher upon approval. It's creative but I don't think they should be eligible for a PRV this way. One of the points in the legislation is that the application "does not seek approval for an adult indication in the original rare pediatric disease product application". There have been a few precedent setting approvals for PRVs in the last few years so I cant be sure here that they wouldn't be PRV eligible, perhaps arguing that these are two distinct indications and just happen to be filing together is a PRV-eligible approach 🤷♂️. Very interested to see how the FDA handles this one, a PRV issuance here could set the precedent and direction for how other companies approach their trial sequencing and development plan. I can think of at least one other company off-hand that would immediately change their filing approach for their asset if this approach works in getting a PRV.



Saw a clinical-stage biotech CEO speak today and what I hadn’t fully appreciated is that a biotech CEO is the ultimate salesperson. Most biotechs fail and raising is brutal, so being able to raise, again and again, decades before a return is not for those without persistence.
